Literature DB >> 10049250

In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems.

W J Weiss1, P J Petersen, N V Jacobus, Y I Lin, P Bitha, R T Testa.   

Abstract

CL 188,624, CL 190,294, and CL 191,121 are novel aminomethyl tetrahydrofuranyl (THF)-1 beta-methylcarbapenems. The in vitro antibacterial activities of these THF carbapenems were evaluated and compared with those of biapenem, imipenem, and meropenem against 554 recent clinical isolates obtained from geographically distinct medical centers across North America. The antibacterial activities of the THF carbapenems were equivalent to that of biapenem, and the THF carbapenems were slightly more active than imipenem and less active than meropenem against most of the members of the family Enterobacteriaceae but lacked significant activity against Pseudomonas isolates. In general, CL 191,121 was two- to fourfold more active than CL 188,624 and CL 190,294 against the staphylococcal and enterococcal isolates tested. CL 191,121 was twofold less active than imipenem against methicillin-susceptible staphylococci and was as activity as imipenem against Enterococcus faecalis isolates. Biapenem and meropenem were two- and fourfold less active than CL 191,121, respectively, against the methicillin-susceptible staphylococci and E. faecalis. All the carbapenems displayed equivalent good activities against the streptococci. Biapenem was slightly more active than the other carbapenems against Bacteroides fragilis isolates. Time-kill curve studies demonstrated that the THF carbapenems were bactericidal in 6 h against Escherichia coli and Staphylococcus aureus isolates. The postantibiotic effect exerted by CL 191,121 was comparable to or slightly longer than that of imipenem against isolates of S. aureus, E. coli, and Klebsiella pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049250      PMCID: PMC89143     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Problems and dilemmas of antimicrobial resistance.

Authors:  B E Murray
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

2.  In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.

Authors:  P J Petersen; N V Jacobus; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.

Authors:  X Y Zhou; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

4.  In-vitro studies of meropenem.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

5.  Interactions of meropenem, with beta-lactamases, including enzymes with extended-spectrum activity against third-generation cephalosporins.

Authors:  R Labia; A Morand; K Tiwari; D Sirot; C Chanal
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

6.  In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

Authors:  M Tsuji; Y Ishii; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

7.  Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs.

Authors:  H S Sader; R N Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

8.  Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex.

Authors:  M Hikida; K Kawashima; M Yoshida; S Mitsuhashi
Journal:  J Antimicrob Chemother       Date:  1992-08       Impact factor: 5.790

9.  Inhibition of the mammalian beta-lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted-propenoic acids.

Authors:  D W Graham; W T Ashton; L Barash; J E Brown; R D Brown; L F Canning; A Chen; J P Springer; E F Rogers
Journal:  J Med Chem       Date:  1987-06       Impact factor: 7.446

10.  In vitro activity and beta-lactamase stability of LJC 10,627.

Authors:  H C Neu; J W Gu; W Fang; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

View more
  6 in total

1.  Biochemical characterization of novel tetrahydrofuranyl 1beta-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial beta-lactamases, binding to penicillin binding proteins, and permeability properties.

Authors:  Y Yang; R T Testa; N Bhachech; B A Rasmussen; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  In vitro antibacterial activity of LJC 11,036, an active metabolite of L-084, a new oral carbapenem antibiotic with potent antipneumococcal activity.

Authors:  M Hikida; K Itahashi; A Igarashi; T Shiba; M Kitamura
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 3.  Biapenem.

Authors:  Caroline M Perry; Tim Ibbotson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  In vitro and in vivo antibacterial activities of L-084, a novel oral carbapenem, against causative organisms of respiratory tract infections.

Authors:  S Miyazaki; T Hosoyama; N Furuya; Y Ishii; T Matsumoto; A Ohno; K Tateda; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 5.  Meropenem: an updated review of its use in the management of intra-abdominal infections.

Authors:  M N Lowe; H M Lamb
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

6.  Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner.

Authors:  Huanrong Hu; Zhen Dong; Peng Tan; Yanli Zhang; Lichao Liu; Liqun Yang; Yaling Liu; Hongjuan Cui
Journal:  Oncotarget       Date:  2016-01-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.